DellaFortuna Felicia purchased $19K of WW

DellaFortuna Felicia (CFO & Member, IOCE) purchased 1,500 shares of WW INTERNATIONAL, INC. (WW) at $12.68 on 2026-05-22.

Original reporting
SEC EDGAR · DellaFortuna Felicia
Published May 27, 2026, 8:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$WW
Bullish
medium confidence
Mentioned
$WW
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$WWBullishLow
01

Why it matters

An officer/direct insider open-market purchase can modestly support sentiment, but without accompanying company-specific fundamentals it is unlikely to materially change valuation.

02

Market read

Traders may note the insider buy as a small positive signal, but the lack of new fundamentals limits trading edge.

03

What to watch

No 10b5-1 plan is cited, but the filing alone doesn’t confirm intent, and the article lacks context on prior insider activity or total holdings changes beyond this lot.

Relevance 6/10Timing: Immediate (new Form 4 filed 2026-05-27) but unlikely to drive sustained repricing without additional catalysts.

Background

The article is a SEC Form 4 insider transaction disclosure for WW International, Inc.

Company-level read

Ticker impact

$WWBullishMedium confidence
Context

WW International CFO Felicia DellaFortuna filed an open-market purchase of 1,500 shares at $12.6750 on 2026-05-22.

Expected impact

Mild positive bias; any reaction is likely short-lived unless followed by larger buys or fundamental catalysts.

Evidence & confidence

Form 4 insider purchases can signal confidence, but the article provides no new operational or financial information and the disclosed size/value is modest.

Market effects

Minimal; insider buying in a single company typically does not reset sector expectations.

None indicated; transaction is company-specific and US-listed.

None indicated; no cross-border deal or regulatory event mentioned.

Counterpoint

The purchase may reflect routine portfolio rebalancing or personal liquidity needs rather than a forward-looking view.

Key entities

  • WW International, Inc.

    Subject of the Form 4 insider purchase by CFO & IOCE Felicia DellaFortuna.

  • Felicia DellaFortuna

    CFO & Member (IOCE) who purchased 1,500 shares at $12.6750 on 2026-05-22.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WWMedAI 8/10

What WW International (WW) Said on Its Q3 Earnings Call

WW International reported Q3 earnings, highlighting a 40% YoY increase in clinical subscribers to 174,000, though down from 197,000 in Q2. Behavioral subscription revenue fell 22% to $113.9M, while clinical revenue rose 48% to $38M. Adjusted gross margin reached 74.6%, and marketing expenses declined. The company narrowed its 2026 revenue guidance to $625M-$630M and adjusted EBITDA to $110M-$115M. Cash increased to $126.4M, and debt was reduced by 70%.

$WWMedAI 8/10

WW International Inc (WW) (Q3 2026) Earnings Call Highlights: Clinical Revenue Surges 48%

WW International reported Q3 2026 revenue of $152.9M, down 11% YoY, with behavioral subscription revenue dropping 22%. Clinical revenue surged 48%, but clinical subscribers declined sequentially. Full-year revenue guidance was narrowed to $625-$630M. Core+ subscribers grew 16% YoY, driven by GLP-1 program adoption and virtual experiences. The company expects flat gross margins at ~74% despite clinical mix growth.

$WWMed

WW International, Inc. Q3 2026 Earnings Call Summary

WW International reported Q3 2026 earnings, highlighting a strategic shift to higher-value tiers (Core+ and Med+) generating 50% of revenue. Clinical revenue grew 48% YoY, driven by Med+ and GLP-1 Success Program. Core+ saw subscriber growth for four consecutive quarters. The company expects sustainable growth in 2027, with clinical revenues projected to reach 25% of total revenue. Debt reduced by 70% since 2025, and net income turned positive.